Zobrazeno 1 - 10
of 31
pro vyhledávání: '"BUZDAR, A"'
Autor:
Chlebowski R; Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California 90502, USA. rchlebowski@gmail.com, Cuzick J, Amakye D, Bauerfeind I, Buzdar A, Chia S, Cutuli B, Linforth R, Maass N, Noguchi S, Robidoux A, Verma S, Hadji P
Publikováno v:
Breast (Edinburgh, Scotland) [Breast] 2009 Aug; Vol. 18 Suppl 2, pp. S1-11.
Autor:
Yamaya H; Pharmacokinetics Research Laboratory, Taiho Pharmaceutical Co., Ltd, Tokushima, Japan. hide-yamaya@taiho.co.jp, Yoshida K, Kuritani J, Yonezawa J, Tsuda M, Shindo T, Nagayama S, Buzdar AU
Publikováno v:
Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2005 Oct; Vol. 30 (5), pp. 459-70.
Autor:
Roseman BJ; Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA., Buzdar AU, Singletary SE
Publikováno v:
Journal of surgical oncology [J Surg Oncol] 1997 Nov; Vol. 66 (3), pp. 215-20.
Autor:
Tanda M, Dudenkov, Duan, Liu, Junmei, Cairns, Sandhya, Devarajan, Yongxian, Zhuang, James N, Ingle, Aman U, Buzdar, Mark E, Robson, Michiaki, Kubo, Anthony, Batzler, Poulami, Barman, Gregory D, Jenkins, Erin E, Carlson, Matthew P, Goetz, Donald W, Northfelt, Alvaro, Moreno-Aspitia, Zeruesenay, Desta, Joel M, Reid, Krishna R, Kalari, Liewei, Wang, Richard M, Weinshilboum
Publikováno v:
Clinical Pharmacology and Therapeutics
Anastrozole is a widely prescribed aromatase inhibitor for the therapy of estrogen receptor positive (ER+) breast cancer. We performed a genome‐wide association study (GWAS) for plasma anastrozole concentrations in 687 postmenopausal women with ER+
Autor:
Edith A. Perez, Krishna R. Kalari, Donald Northfelt, Aman U. Buzdar, Tanda T. Dudenkov, Liewei Wang, Zeruesenay Desta, Richard M. Weinshilboum, Matthew P. Goetz, Clark V. Williard, James N. Ingle, Poulami Barman, Mark E. Robson, David A. Flockhart
Publikováno v:
Steroids. 99:32-38
We determined hormone concentrations (estradiol [E2], estrone [E1], estrone conjugates [E1-C], androstenedione [A], testosterone [T]) before and on anastrozole therapy where we also determined plasma concentrations of anastrozole and its metabolites.
Autor:
H, Yamaya, K, Yoshida, J, Kuritani, J, Yonezawa, J-I, Yonezawa, M, Tsuda, T, Shindo, S, Nagayama, A U, Buzdar
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 30:459-470
Summary Objectives: The present study was conducted to evaluate the safety, tolerability, and pharmacokinetics of TAS-108 after ascending single oral doses and to analyse preliminarily the effect of food on the pharmacokinetics of TAS-108 in normal h
Autor:
John F.R. Robertson, Aman U. Buzdar, Stephen E. Jones, Matthew J. Ellis, Alan Webster, Louis Mauriac, Stan Gertler, Steven E. Come, Anthony Howell, Charles A. Morris, Ignace Vergote, Ulrich R. Kleeberg, C. Kent Osborne
Publikováno v:
Cancer. 98:229-238
BACKGROUND Fulvestrant (ICI 182,780) is a new type of estrogen receptor (ER) antagonist that down-regulates the ER and has no known agonist effects. The authors report the prospectively planned combined analysis of data from 2 Phase III trials compar
Autor:
Eleftherios P. Mamounas, Michael Baum, Mitchell Dowsett, Anthony Howell, Generosa Grana, Robert W. Carlson, Richard M. Elledge, William J. Gradishar, D. Craig Allred, Aman U. Buzdar
Publikováno v:
The Breast Journal. 9:213-222
This article summarizes the conclusions of a meeting of diverse breast cancer experts who discussed issues, controversies, and new clinical trial results relevant to the use of aromatase inhibitors for treating postmenopausal women with breast cancer
Autor:
Pedro Bassa, Tomio Inoue, Donald A. Podoloff, Aman U. Buzdar, E. Edmund Kim, David J. Yang, Sidney Wallace, Franklin C. Wong
Publikováno v:
Clinical Imaging. 21:332-336
The clinical meaning of cardiac uptake of [18F]fluorotamoxifen was assessed. Tamoxifen, a nonsteroidal antiestrogenic drug for treatment and prevention of breast cancer, has a cardioprotective, estrogen-like effect in postmenopausal women. We conduct